Sponsored by
I love this company's plan: they look at failed trials that had some patients do well, and figure out why they failed and which patients benefit. Then they run the trial only on those patients predicted to have a good outcome. One of their first projects is to take Toca511 and TocaFC (now called DB107) and start a trial only for people with the correct biomarker. They did not yet annoucne the biomarker - when they do we can spread word of it and notify people in our database who have that marker. The original early trials of Toca511 looked bery good. I know of a few patients in the trial that did pretty well. However, their large phase 3 randomized trial failed. At that time they did not know which biomarkers predicted success but now they do. It did not help the average patient, but it did help a long tail of people who did have this biomarker!